What was reported
The assessment describes donor-directed annealing with prime editing for large genomic replacement. One reported application was targeted CAR insertion into primary human T cells, with efficiency up to 28.1%. [C09]
What the result does not establish
Cell-line maxima, primary-cell results and mouse delivery are different experiments. They cannot be combined into one general performance promise or a claim of age reversal.
Measured endpoint
Large-fragment integration, replacement and context-specific editing efficiency.
Karam’s next question
What is the useful output in the exact target cell type, and which unintended integration outcomes require measurement?
Assessment-derived brief. Cited in the supplied 15 October 2026 project assessment; not independently reviewed in this website release. Karam has not reproduced the experiment or independently audited the underlying dataset. This is not Karam-generated evidence.
